Stomach Cancer Treatments

Find Stomach Cancer Treatments

Generic Name

Trastuzumab

Brand Names

Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera

FDA approval date: February 10, 2017

Classification: HER2/neu Receptor Antagonist

Form: Injection, Kit

What is Herceptin (Trastuzumab)?

Herceptin is a HER2/neu receptor antagonist indicated for: The treatment of HER2-overexpressing breast cancer.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Who is this study for: Patients with HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Procedure, Drug, Radiation, Other

Study Drugs: Carboplatin, Hyaluronidase-zzxf+Pertuzumab+Trastuzumab, Paclitaxel, Trastuzumab+Hyaluronidase-oysk

Study Phase: Phase 3

Summary: This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to spe...

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Who is this study for: Adolescents or young adults with recurrent HER2+ osteosarcoma

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Procedure, Biological

Study Drug: Trastuzumab Deruxtecan

Study Phase: Phase 2

Summary: This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Trastuzumab deruxtecan is in a class of medications called antibody-drug...

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Behavioral

Study Phase: Not Applicable

Summary: The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into c...

View All Clinical Trials

Related Latest Advances

Title Not Found

Journal: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke

Published: September 08, 2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 03, 2026

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

Journal: The American journal of case reports

Published: September 02, 2026

View All Latest Advances

Brand Information

Herceptin (Trastuzumab)

1DOSAGE FORMS AND STRENGTHS

For injection: 150 mg white to pale yellow lyophilized powder in a single-dose vial

2CONTRAINDICATIONS

None.

3ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label:

Cardiomyopathy
Infusion Reactions
Embryo-Fetal Toxicity
Pulmonary Toxicity
Exacerbation of Chemotherapy-Induced Neutropenia

3.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions in patients receiving Herceptin in the adjuvant and metastatic breast cancer setting are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia. Adverse reactions requiring interruption or discontinuation of Herceptin treatment include CHF, significant decline in left ventricular cardiac function, severe infusion reactions, and pulmonary toxicity

In the metastatic gastric cancer setting, the most common adverse reactions (≥ 10%) that were increased (≥ 5% difference) in the Herceptin arm as compared to the chemotherapy alone arm were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.

The most common adverse reactions which resulted in discontinuation of treatment on the Herceptin-containing arm in the absence of disease progression were infection, diarrhea, and febrile neutropenia.

3.2Post-Marketing Experience

The following adverse reactions have been identified during post-approval use of Herceptin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infusion reaction
Oligohydramnios or oligohydramnios sequence, including pulmonary hypoplasia, skeletal abnormalities, and neonatal death
Glomerulopathy
Immune thrombocytopenia
Tumor lysis syndrome (TLS): Cases of possible TLS have been reported in patients treated with Herceptin. Patients with significant tumor burden (e.g. bulky metastases) may be at a higher risk. Patients could present with hyperuricemia, hyperphosphatemia, and acute renal failure which may represent possible TLS. Providers should consider additional monitoring and/or treatment as clinically indicated.

4DESCRIPTION

Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture.

Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.

Each single-dose vial of Herceptin delivers 150 mg trastuzumab, 136.2 mg α,α-trehalose dihydrate, 3.4 mg L-histidine HCl monohydrate, 2.2 mg L-histidine, and 0.6 mg polysorbate 20. Reconstitution with 7.4 mL of sterile water for injection (SWFI) yields a solution containing 21 mg/mL trastuzumab that delivers 7.15 mL (150 mg trastuzumab), at a pH of approximately 6.

5PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton

NDC 50242-132-01

Herceptin

150 mg per vial

For Intravenous Infusion

Single-Dose Vial.

No preservative.

KEEP REFRIGERATED

Genentech

10187107

PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton